ClearPoint Neuro, Inc. (CLPT)

NASDAQ: CLPT · Real-Time Price · USD
11.92
+1.38 (13.09%)
At close: Aug 13, 2025, 4:00 PM
11.85
-0.07 (-0.59%)
After-hours: Aug 13, 2025, 5:04 PM EDT
13.09%
Market Cap 299.58M
Revenue (ttm) 33.59M
Net Income (ttm) -22.22M
Shares Out 28.42M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 867,188
Open 10.71
Previous Close 10.54
Day's Range 10.46 - 11.95
52-Week Range 9.40 - 19.22
Beta 0.85
Analysts Strong Buy
Price Target 27.67 (+132.13%)
Earnings Date Aug 12, 2025

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; li... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1998
Employees 115
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2024, ClearPoint Neuro's revenue was $31.39 million, an increase of 31.04% compared to the previous year's $23.96 million. Losses were -$18.91 million, -14.37% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price target is $27.67, which is an increase of 132.13% from the latest price.

Price Target
$27.67
(132.13% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Fi...

18 hours ago - Seeking Alpha

ClearPoint Neuro Reports Second Quarter 2025 Results

Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...

1 day ago - Accesswire

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

9 days ago - Accesswire

ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation ...

21 days ago - Accesswire

ClearPoint Neuro: Consumables Growth Is Promising

ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of ...

6 weeks ago - Seeking Alpha

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

3 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief F...

3 months ago - Seeking Alpha

ClearPoint Neuro Reports First Quarter 2025 Results

Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),...

3 months ago - Accesswire

ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation t...

3 months ago - Accesswire

ClearPoint Neuro: Fundamentals Continue To Strengthen

ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their thera...

3 months ago - Seeking Alpha

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI

SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

3 months ago - Accesswire

ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025

SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

3 months ago - Accesswire

ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room

The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / April 24, 2025 / ClearPoint ...

3 months ago - Accesswire

ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen

ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical...

5 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank ...

5 months ago - Seeking Alpha

ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results

Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...

6 months ago - Accesswire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

6 months ago - Accesswire

ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula

SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

6 months ago - Accesswire

ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...

7 months ago - Accesswire

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...

9 months ago - Accesswire

ClearPoint Neuro: Near-Term Volatility Is No Concern

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near ...

9 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Fi...

9 months ago - Seeking Alpha

ClearPoint Neuro Reports Third Quarter 2024 Results

Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a glob...

9 months ago - Accesswire

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CL...

10 months ago - Accesswire

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

10 months ago - GlobeNewsWire